{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,8]],"date-time":"2026-10-08T11:11:27Z","timestamp":1791457887435,"version":"4.3.4"},"reference-count":29,"publisher":"American Society of Clinical Oncology (ASCO)","issue":"29","content-domain":{"domain":["ascopubs.org"],"crossmark-restriction":true},"short-container-title":["J Clin Oncol"],"published-print":{"date-parts":[[2026,10,10]]},"abstract":"<jats:sec>\n                    <jats:title>PURPOSE<\/jats:title>\n                    <jats:p>Immunotherapy for frontline mismatch repair\u2013deficient\/microsatellite instability-high (dMMR\/MSI-H) metastatic colorectal cancer (mCRC) is effective; however, nearly half of the patients treated with single-agent PD-1 therapy will progress within 12 months. Preclinical studies in CRC and clinical data from other cancers suggest that vascular endothelial growth factor inhibition and chemotherapy can synergize with PD-L1 inhibition.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>METHODS<\/jats:title>\n                    <jats:p>The NRG-GI004\/SWOG-S1610 (COMMIT) three-arm prospective phase III open-label trial randomly assigned first-line dMMR\/MSI-H mCRC patients (1:1:1) to either: mFOLFOX6 (oxaliplatin 85 mg\/m\u00b2, leucovorin 400 mg\/m\u00b2, 5-FU bolus 400 mg\/m\u00b2, and 46-hour infusional 5-FU 2,400 mg\/m\u00b2)\/bevacizumab (FFX\/bev), or atezolizumab (atezo) monotherapy (840 mg IV once every 2 weeks), or the combination of FFX\/bev\/atezo. The primary end point was progression-free survival (PFS) in the intent-to-treat population. Because of KEYNOTE 177 results, the FFX\/bev arm was closed after 20 patients were enrolled. The study continued with atezo alone versus FFX\/bev\/atezo, with a revised sample size of 100 patients in the two remaining arms (120 patients across all three arms).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>RESULTS<\/jats:title>\n                    <jats:p>\n                      From November 2017 to March 2025, a total of 102 patients were enrolled in the three arms: FFX\/bev: n = 20, atezo: n = 41, and FFX\/bev\/atezo: n = 41. At a median follow-up of 46 months for the two arms (median age: 63.3 years; 47.6% female; 23.2%\n                      <jats:italic toggle=\"yes\">BRAF V600E<\/jats:italic>\n                      mutated), PFS of FFX\/bev\/atezo was superior to that of atezo (hazard ratio [HR], 0.439 [95% CI, 0.23 to 0.84];\n                      <jats:italic toggle=\"yes\">P<\/jats:italic>\n                      = .0103) and below the critical value of 0.0152. The objective response rate was 86.1% versus 46%, and the disease control rate at 12 months was 64.7% versus 32.4% in the FFX\/bev\/atezo arm compared with the atezo-only arm, respectively. Grade 3 or higher adverse events of any attribution occurred in 52 patients (atezo: 18; combination arm: 34).\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>CONCLUSION<\/jats:title>\n                    <jats:p>The combination of FFX\/bev plus atezo led to significantly longer PFS compared with atezo monotherapy in the first-line treatment of dMMR\/MSI-H mCRC.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1200\/jco-25-03052","type":"journal-article","created":{"date-parts":[[2026,7,29]],"date-time":"2026-07-29T20:00:53Z","timestamp":1785355253000},"page":"2824-2834","update-policy":"https:\/\/doi.org\/10.1200\/crossmark","source":"Crossref","is-referenced-by-count":1,"title":["COMMIT: A Randomized Study of mFOLFOX6\/Bevacizumab\/Atezolizumab or Atezolizumab Alone as First-Line Treatment of Deficient DNA Mismatch Repair Metastatic Colorectal Cancer"],"prefix":"10.1200","volume":"44","clinical-trial-number":[{"clinical-trial-number":"nct02997228","registry":"10.18810\/clinical-trials-gov"}],"author":[{"ORCID":"https:\/\/orcid.org\/0009-0007-4681-1705","authenticated-orcid":false,"given":"Caio Max Sao Pedro","family":"Rocha Lima","sequence":"first","affiliation":[{"name":"Atrium Health Wake Forest University Baptist Comprehensive Cancer Center, Winston-Salem, NC"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7965-7333","authenticated-orcid":false,"given":"Greg","family":"Yothers","sequence":"additional","affiliation":[{"name":"NRG Oncology SDMC, Pittsburgh, PA"},{"name":"Department of Biostatistics and Health Data Science, University of Pittsburgh, Pittsburgh, PA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6249-9180","authenticated-orcid":false,"given":"Thomas J.","family":"George","sequence":"additional","affiliation":[{"name":"University of Florida Health Cancer Institute, Gainesville, FL"},{"name":"NSABP Foundation, Inc, Pittsburgh, PA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9893-1529","authenticated-orcid":false,"given":"Howard S.","family":"Hochster","sequence":"additional","affiliation":[{"name":"Rutgers Cancer Institute of New Jersey, New Brunswick, NJ"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8679-4486","authenticated-orcid":false,"given":"Hanna K.","family":"Sanoff","sequence":"additional","affiliation":[{"name":"Lineberger Comprehensive Cancer Center, University of North Carolina at Chapel Hill, Chapel Hill, NC"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6178-9266","authenticated-orcid":false,"given":"Deirdre J.","family":"Cohen","sequence":"additional","affiliation":[{"name":"Tisch Cancer Center; Icahn School of Medicine at Mount Sinai, New York, NY"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7257-8280","authenticated-orcid":false,"given":"Katherine A.","family":"Guthrie","sequence":"additional","affiliation":[{"name":"Fred Hutchinson Cancer Center; and SWOG Statistics and Data Management Center, Seattle, WA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Samuel A.","family":"Jacobs","sequence":"additional","affiliation":[{"name":"NSABP Foundation, Inc, Pittsburgh, PA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8024-9401","authenticated-orcid":false,"given":"Anwaar","family":"Saeed","sequence":"additional","affiliation":[{"name":"NSABP Foundation, Inc, Pittsburgh, PA"},{"name":"University of Pittsburgh School of Medicine, UPMC Hillman Cancer Center, Pittsburgh, PA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9647-3416","authenticated-orcid":false,"given":"Scott","family":"Kopetz","sequence":"additional","affiliation":[{"name":"The University of Texas MD Anderson Cancer Center, Houston, TX"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Linda H.","family":"Colangelo","sequence":"additional","affiliation":[{"name":"NRG Oncology SDMC, Pittsburgh, PA"},{"name":"Department of Biostatistics and Health Data Science, University of Pittsburgh, Pittsburgh, PA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tanner J.","family":"Freeman","sequence":"additional","affiliation":[{"name":"NSABP Foundation, Inc, Pittsburgh, PA"},{"name":"Department of Pathology, University of Pittsburgh, Pittsburgh, PA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Scott W.","family":"Cole","sequence":"additional","affiliation":[{"name":"Oklahoma Cancer Specialists and Research Institute, Tulsa, OK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maged","family":"Khalil","sequence":"additional","affiliation":[{"name":"Lehigh Valley-Cedar Crest Hospital, Allentown, PA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Swapna","family":"Devanna","sequence":"additional","affiliation":[{"name":"United Hospital, St Paul, MN"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4005-1764","authenticated-orcid":false,"given":"Dan S.","family":"Zuckerman","sequence":"additional","affiliation":[{"name":"St Luke's Cancer Institute, Boise, ID"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8481-6581","authenticated-orcid":false,"given":"Theodore S.","family":"Hong","sequence":"additional","affiliation":[{"name":"Dana-Farber Cancer Institute and Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, MA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4771-5930","authenticated-orcid":false,"given":"N. Lynn","family":"Henry","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine, University of Michigan Medical School, Ann Arbor, MI"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1841-4143","authenticated-orcid":false,"given":"Patricia A.","family":"Ganz","sequence":"additional","affiliation":[{"name":"David Geffen School of Medicine at UCLA, Los Angeles, CA"},{"name":"UCLA Fielding School of Public Health, Los Angeles, CA"},{"name":"UCLA Jonsson Comprehensive Cancer Center, Los Angeles, CA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Charles D.","family":"Blanke","sequence":"additional","affiliation":[{"name":"Oregon Health &amp; Science University School of Medicine, Knight Cancer Center, Portland, OR"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7156-1110","authenticated-orcid":false,"given":"Norman","family":"Wolmark","sequence":"additional","affiliation":[{"name":"NSABP Foundation, Inc, Pittsburgh, PA"},{"name":"University of Pittsburgh School of Medicine, UPMC Hillman Cancer Center, Pittsburgh, PA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5377-135X","authenticated-orcid":false,"given":"Michael J.","family":"Overman","sequence":"additional","affiliation":[{"name":"The University of Texas MD Anderson Cancer Center, Houston, TX"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"233","reference":[{"key":"e_1_3_14_2_2","article-title":"The prevalence and prognosis of microsatellite instability-high\/mismatch repair-deficient colorectal adenocarcinomas in the United States","author":"Gutierrez C","unstructured":"Gutierrez C, Ogino S, Meyerhardt JA, et al: The prevalence and prognosis of microsatellite instability-high\/mismatch repair-deficient colorectal adenocarcinomas in the United States. JCO Precis Oncol 10.1200\/PO.22.00179","journal-title":"JCO Precis Oncol"},{"key":"e_1_3_14_3_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMcp1714533"},{"key":"e_1_3_14_4_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2017699"},{"key":"e_1_3_14_5_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2400634"},{"key":"e_1_3_14_6_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(24)02848-4"},{"key":"e_1_3_14_7_2","doi-asserted-by":"publisher","DOI":"10.1002\/jcp.28585"},{"key":"e_1_3_14_8_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.bbrc.2016.12.180"},{"key":"e_1_3_14_9_2","doi-asserted-by":"publisher","DOI":"10.1080\/2162402X.2018.1433981"},{"key":"e_1_3_14_10_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2507874"},{"key":"e_1_3_14_11_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.intimp.2025.114212"},{"key":"e_1_3_14_12_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1915745"},{"key":"e_1_3_14_13_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1716948"},{"key":"e_1_3_14_14_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(19)30723-8"},{"key":"e_1_3_14_15_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1816714"},{"key":"e_1_3_14_16_2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2017.35.4_suppl.673"},{"key":"e_1_3_14_17_2","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(22)00274-1"},{"key":"e_1_3_14_18_2","doi-asserted-by":"publisher","DOI":"10.1200\/jco.2015.33.3_suppl.704"},{"key":"e_1_3_14_19_2","doi-asserted-by":"publisher","DOI":"10.1038\/cdd.2013.67"},{"key":"e_1_3_14_20_2","doi-asserted-by":"publisher","DOI":"10.1038\/s41571-024-00886-y"},{"key":"e_1_3_14_21_2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2017.76.9901"},{"key":"e_1_3_14_22_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2402141"},{"key":"e_1_3_14_23_2","article-title":"Nivolumab (NIVO) plus ipilimumab (IPI) vs chemotherapy (chemo) as first-line (1L) treatment for microsatellite instability-high\/mismatch repair-deficient (MSI-H\/dMMR) metastatic colorectal cancer (mCRC): Expanded efficacy analysis from CheckMate 8HW","volume":"42","author":"Lenz H-J","year":"2024","unstructured":"Lenz H-J, Lonardi S, Elez E, et al: Nivolumab (NIVO) plus ipilimumab (IPI) vs chemotherapy (chemo) as first-line (1L) treatment for microsatellite instability-high\/mismatch repair-deficient (MSI-H\/dMMR) metastatic colorectal cancer (mCRC): Expanded efficacy analysis from CheckMate 8HW. J Clin Oncol 42, 2024 (suppl 16; abstr 3503)","journal-title":"J Clin Oncol"},{"key":"e_1_3_14_24_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.esmoop.2021.100120"},{"key":"e_1_3_14_25_2","doi-asserted-by":"publisher","DOI":"10.3390\/cancers11101567"},{"key":"e_1_3_14_26_2","doi-asserted-by":"publisher","DOI":"10.1038\/s41422-020-0343-4"},{"key":"e_1_3_14_27_2","doi-asserted-by":"publisher","DOI":"10.1038\/s41416-022-02084-y"},{"key":"e_1_3_14_28_2","doi-asserted-by":"publisher","DOI":"10.1126\/science.aav7062"},{"key":"e_1_3_14_29_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejca.2023.02.016"},{"key":"e_1_3_14_30_2","doi-asserted-by":"publisher","DOI":"10.1001\/jamaoncol.2023.2761"}],"container-title":["Journal of Clinical Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/ascopubs.org\/doi\/pdfdirect\/10.1200\/JCO-25-03052","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,10,7]],"date-time":"2026-10-07T22:00:33Z","timestamp":1791410433000},"score":1,"resource":{"primary":{"URL":"https:\/\/ascopubs.org\/doi\/10.1200\/JCO-25-03052"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,10,10]]},"references-count":29,"journal-issue":{"issue":"29","published-print":{"date-parts":[[2026,10,10]]}},"alternative-id":["10.1200\/JCO-25-03052"],"URL":"https:\/\/doi.org\/10.1200\/jco-25-03052","relation":{},"ISSN":["0732-183X","1527-7755"],"issn-type":[{"value":"0732-183X","type":"print"},{"value":"1527-7755","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,10,10]]},"assertion":[{"value":"2025-12-19","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2026-06-03","order":1,"name":"revised","label":"Revised","group":{"name":"publication_history","label":"Publication History"}},{"value":"2026-06-24","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2026-07-29","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}